Among the fibrosis markers tested, TIMP-1 showed a consistent significant decrease in all three I-BET151 treated groups in the fibrosis study (p < 0.05, one way ANOVA followed by Fisher LSD test), and COL1A1 showed a suggestive, but non-significant decrease following treatment in both the NASH and fibrosis studies. This evidence concerns the gene COL1A1 and metabolic dysfunction-associated steatohepatitis.